Results 31 to 40 of about 1,734 (194)

Enhanced Characterization of Drug Metabolism and the Influence of the Intestinal Microbiome: A Pharmacokinetic, Microbiome, and Untargeted Metabolomics Study. [PDF]

, 2020
Determining factors that contribute to interindividual and intra-individual variability in pharmacokinetics (PKs) and drug metabolism is essential for the optimal use of drugs in humans.
Alhaja, Maher, Dorrestein, Pieter C, Jarmusch, Alan K, Knight, Rob, Liyanage, Marlon, Ma, Joseph D, Momper, Jeremiah D, Tsunoda, Shirley M, Vrbanac, Alison   +8 more
core   +1 more source

New Treatment Options for Refractory/Resistant CMV Infection

Transplant International, 2023
Despite advances in monitoring and treatment, cytomegalovirus (CMV) infections remain one of the most common complications after solid organ transplantation (SOT).
Carla Simone Walti, Nina Khanna, Robin K. Avery, Ilkka Helanterä   +3 more
doaj   +1 more source

Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients [PDF]

, 2023
Background: This drug resistance analysis of a randomized trial includes 234 patients receiving maribavir and 116 receiving investigator-assigned standard therapy (IAT), where 56% and 24%, respectively, cleared cytomegalovirus DNA at week 8 (treatment ...
Alain, Sophie, Buss, Neil E, Cervera, Carlos, Chemaly, Roy F, Chou, Sunwen, Fournier, Martha, Kotton, Camille N, Lundgren, Jens, Murray, Rose Ann, Papanicolaou, Genovefa A, Pereira, Marcus R, Wu, Jingyang J   +11 more
core   +2 more sources

Population pharmacokinetic modeling and simulation of maribavir to support dose selection and regulatory approval in adolescents with posttransplant refractory cytomegalovirus

CPT: Pharmacometrics & Systems Pharmacology, 2023
Maribavir was approved by the US Food and Drug Administration for the treatment of patients aged ≥12 years and weighing ≥35 kg with posttransplant cytomegalovirus infection/disease refractory (with/without resistance) to valganciclovir, ganciclovir ...
Kefeng Sun, Siobhan Hayes, Colm Farrell, Ivy H. Song   +3 more
doaj   +1 more source

Unraveling Cytomegalovirus Drug Resistance in Transplant Patients by Targeting Deep Sequencing. [PDF]

J Med Virol
ABSTRACT Drug‐resistant cytomegalovirus (CMV) poses a major clinical challenge in transplant recipients, leading to treatment failure and increased morbidity. This study applied a next‐generation sequencing (NGS) approach to identify antiviral resistance mutations (ARMs) in 71 samples from 68 CMV‐positive patients who had undergone hematopoietic stem ...
Alemán S, Camacho J, Recio V, Ruiz E, Zamarrón P, Anel J, Enjuto M, Tarragó D.   +7 more
europepmc   +2 more sources

Anti-CMV therapy, what next? A systematic review

Frontiers in Microbiology, 2023
Human cytomegalovirus (HCMV) is one of the main causes of serious complications in immunocompromised patients and after congenital infection. There are currently drugs available to treat HCMV infection, targeting viral polymerase, whose use is ...
Claire Gourin, Sophie Alain, Sophie Alain, Sébastien Hantz, Sébastien Hantz   +4 more
doaj   +1 more source

[Cost-Effectiveness Analysis of Maribavir in Patients with Post-Transplant Cytomegalovirus Infection or Disease that are Refractory or Resistant to Conventional Therapy] [PDF]

, 2023
OBJECTIVES: Cytomegalovirus (CMV) infection represents a serious post-transplantation complication, particularly among transplant recipients with resistant or refractory (R/R) infection.
Amorosi, Stacey L., Bini, Chiara, Chowdhury, Emtiyaz, Corinti, Simone, Dalla Vedova, Laura, De Lacey, Tam, Fioravanti, Laura, Marcellusi, Andrea, Mennini, Francesco Saverio   +8 more
core   +2 more sources

Retrospective chart review of transplant recipients with cytomegalovirus infection who received maribavir in the Phase 3 SOLSTICE trial: Data at 52 weeks post-maribavir treatment initiation

Antiviral Therapy, 2023
Background Cytomegalovirus (CMV) infection is a frequent complication in haematopoietic cell/solid organ transplant (HCT/SOT) recipients. Previous studies report all-cause mortality rates of 31% and 50% in HCT/SOT recipients post-treatment initiation ...
Marielle Bassel, Dorothy Romanus, Tien Bo, Aimee K Sundberg, Sandra Okala, Ishan Hirji   +5 more
doaj   +1 more source

Identification of lead anti-human cytomegalovirus compounds targeting MAP4K4 via machine learning analysis of kinase inhibitor screening data [PDF]

, 2018
Chemogenomic approaches involving highly annotated compound sets and cell based high throughput screening are emerging as a means to identify novel drug targets.
Al-Ali, H, Asquith, CRM, Ho, CMK, Moshrif, HM, Strang, BL, Zuercher, WJ   +5 more
core   +1 more source

Cytomegalovirus infection is common in prostate cancer and antiviral therapies inhibit progression in disease models. [PDF]

Mol Oncol
Human cytomegalovirus infection is common in normal prostate epithelium, prostate tumor tissue, and prostate cancer cell lines. CMV promotes cell survival, proliferation, and androgen receptor signaling. Anti‐CMV pharmaceutical compounds in clinical use inhibited cell expansion in prostate cancer models in vitro and in vivo, motivating investigation ...
Classon J, Stenudd M, Zamboni M, Alkass K, Eriksson CJ, Pedersen L, Schörling A, Thoss A, Bergh A, Wikström P, Adami HO, Sørensen HT, Druid H, Frisén J.   +13 more
europepmc   +2 more sources